Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2001

View Archived Issues

Millennium granted license to novel target for colorectal cancer

Angiotech to expand phase II study of Paxceed for secondary progressive multiple sclerosis

OSI acquires Gilead's oncology assets

Boehringer Ingelheim and ImmunoGen to develop new TAP product

Phase I trial initiated for nasal administration of interferon beta

Halofuginone enters phase I/II trial for advanced-stage cancer

Lupus kidney disease drug candidate LJP-394 designated an orphan drug in Europe

Squalamine enters phase IIb non-small cell lung cancer trial

Phase II trial of Endostatin for the treatment of neuroendocrine tumors commences

Rec-15/3079 exerts beneficial effects on bladder function without unwanted CNS side effects

Novel peptide antibiotics isolated for the first time from mast cells

Human umbilical cord blood cells in the treatment of stroke

First launch for Lilly's Xigris within days of approval

Novel glutamate AMPA receptor antagonist may have potential in ALS

Morphinan derivatives with high affinity for kappa and mu opioid receptors for Rx of cocaine abuse

Rigel receives milestone from Pfizer for respiratory drug target validation

Regeneron's VEGF Trap enters phase I trial

New class of antifungal agents targeting N-myristoyltransferase designed at Roche

New substituted adenine interferon inducers under study by Japan Energy and Sumitomo

Broad series of 5-HT receptor ligands designed by Pharmacia

Pfizer reveals potential new antiinflammatory/analgesic agents

Japanese patent covers Suntory's new nicotinic acetylcholine receptor agonists

Effective and safe anorectic agents emerge from R&D at Mitsui Chemicals

Novel hydrazide derivatives inhibit apoB-associated lipoprotein secretion

Cell death inhibitors under investigation by Sagami

J-124131: a new antitumor antibiotic identified at Banyu

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.